Summary

Fermenta Biotech Limited, a leading manufacturer of premium-grade APIs, intermediates, and mixes of vitamins and minerals, announced its unaudited financial results for the quarter and nine months ended 31 December 2024. The company reported a consolidated net profit of INR 37.9 crore, a significant increase of 379% YoY and 341% QoQ. The revenue for Q3FY25 was INR 156.46 crore, up 58% YoY and 65% QoQ. The EBITDA for 9MFY25 was INR 80.78 crore, a growth of 183% YoY.

Key Highlights

1. 1

   Consolidated net profit for Q3FY25 is INR 37.9 crore, up 379% YoY and 341% QoQ

2. 2

   Q3FY25 revenue is INR 156.46 crore, up 58% YoY and 65% QoQ

3. 3

   EBITDA for 9MFY25 is INR 80.78 crore, up 183% YoY

4. 4

   Human nutrition volume grew by 102% over Q3FY24 and 71% over 9MFY24

5. 5

   Animal nutrition volume grew by 4% over Q3FY24 and 21% over 9MFY24

6. 6

   German subsidiary showed standalone 9MFY25 revenue of INR 26.5 crore, 383% growth from INR 5.5 crore a year ago, with EBITDA of INR 9.9 crore, against INR 4.9 crore loss for 9MFY24

7. 7

   US subsidiaries showed 9MFY25 revenue of INR 35.8 crore, 80 % growth from INR 19.9 crore for 9MFY24 with EBITDA at INR 1.44 crore, against INR 1.3 crore loss for 9MFY24